Absorption of TAK-491, a new angiotensin II receptor antagonist, in animals

Xenobiotica

Volumn 43, Issue 2, 2013, Pages 182-192

  Kawaguchi, Naohiro ^a   Ebihara, Takuya ^a   Takeuchi, Toshiyuki ^a   Morohashi, Akio ^a   Yamasaki, Hitomi ^a   Tagawa, Yoshihiko ^a   Takahashi, Junzo ^a   Kondo, Takahiro ^a   Asahi, Satoru ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Azilsartan medoxomil; Caco 2; Medoxomil moiety; Permeability; Prodrug; TAK 536

Indexed keywords

AZILSARTAN; AZILSARTAN MEDOXOMIL; DIGOXIN; MANNITOL; METHYLCELLULOSE; OLMESARTAN; PHENAZONE; SERUM ALBUMIN;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG PENETRATION; DRUG STABILITY; DRUG STRUCTURE; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; MALE; MATHEMATICAL ANALYSIS; NONHUMAN; PHARMACOLOGICAL PARAMETERS; RADIOACTIVITY; RAT;

ADMINISTRATION, ORAL; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; CACO-2 CELLS; CARBON RADIOISOTOPES; CELL MEMBRANE PERMEABILITY; DOGS; HUMANS; HYDROLYSIS; INTESTINAL ABSORPTION; INTESTINES; LIVER; MALE; OXADIAZOLES; RATS; RATS, WISTAR; SERUM ALBUMIN;

ANIMALIA; CANIS FAMILIARIS; RATTUS;

EID: 84872168408     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.708797     Document Type: Article

References (13)

1. Ishizuka T, Fujimori I, Kato M, Noji-Sakikawa C, Saito M, Yoshigae Y, Kubota K, Kurihara A, Izumi T, Ikeda T, Okazaki O. (2010). Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine. J Biol Chem 285:11892-11902.
2. Kohara Y, Kubo K, Imamiya E, Wada T, Inada Y, Naka T. (1996). Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. J Med Chem 39:5228-5235. (Pubitemid 27010313)
3. Kondo T, Yoshida K, Yoshimura Y, Motohashi M, Tanayama S. (1996a). Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs. Arzneimittelforschung 46:594-600. (Pubitemid 26201370)
4. Kondo T, Hagiwara K, Kato Y, Yoshida K, Yoshimura Y, Motohashi M, Tanayama S. (1996b). Metabolic fate of TCV-116, a new angiotensin II receptor antagonist, in rats and dogs. Jpn Pharmacol Ther 24:S915.
5. Kubo K, Kohara Y, Yoshimura Y, Inada Y, Shibouta Y, Furukawa Y, Kato T, Nishikawa K, Naka T. (1993). Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7- carboxylic acids. J Med Chem 36:2343-2349. (Pubitemid 23262466)
6. Kusumoto K, Igata H, Ojima M, Tsuboi A, Imanishi M, Yamaguchi F, Sakamoto H, Kuroita T, Kawaguchi N, Nishigaki N, Nagaya H. (2011). Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Eur J Pharmacol 669:84-93.
7. Ma SF, Anraku M, Iwao Y, Yamasaki K, Kragh-Hansen U, Yamaotsu N, Hirono S, Ikeda T, Otagiri M. (2005). Hydrolysis of angiotensin II receptor blocker prodrug olmesartan medoxomil by human serum albumin and identification of its catalytic active sites. Drug Metab Dispos 33:1911-1919. (Pubitemid 41699755)
8. Masungi C, Borremans C, Willems B, Mensch J, Van Dijck A, Augustijns P, Brewster ME, Noppe M. (2004). Usefulness of a novel Caco-2 cell perfusion system. I. In vitro prediction of the absorption potential of passively diffused compounds. J Pharm Sci 93:2507-2521. (Pubitemid 39319434)
9. Miret S, Abrahamse L, de Groene EM. (2004). Comparison of in vitro models for the prediction of compound absorption across the human intestinal mucosa. J Biomol Screen 9:598-606.
10. Ojima M, Igata H, Tanaka M, Sakamoto H, Kuroita T, Kohara Y, Kubo K, Fuse H, Imura Y, Kusumoto K, Nagaya H. (2011). In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 336:801-808.
11. Sankyo Co., Ltd. (2001). 2.9. In vitro hydrolysis of olmesartan medoxomil and RNH-8097 in liver and intestine of rat (Report #GR 146-072). Vol.6. FDA (US) NDA #21, 286: Pharmacology Review(s) 48-49. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2002/21-286-Benicar-pharmr-P2. pdf. Accessed on: 27 December 2011.
12. Skolnik S, Lin X, Wang J, Chen XH, He T, Zhang B. (2010). Towards prediction of in vivo intestinal absorption using a 96-well Caco-2 assay. J Pharm Sci 99:3246-3265.
13. Sun H, Chow EC, Liu S, Du Y, Pang KS. (2008). The Caco-2 cell monolayer: Usefulness and limitations. Expert Opin Drug Metab Toxicol 4:395-411. (Pubitemid 351728514)